<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04575766</url>
  </required_header>
  <id_info>
    <org_study_id>7051-ONC-101</org_study_id>
    <nct_id>NCT04575766</nct_id>
  </id_info>
  <brief_title>A Study of FT-7051 in Men With MCRPC</brief_title>
  <official_title>A Phase 1 Study of FT-7051 in Men With Metastatic Castration-Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Forma Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Forma Therapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, open-label study that will evaluate the safety and tolerability of FT-7051&#xD;
      and determine the recommended Phase 2 dose (RP2D) as well as pharmacokinetics (PK),&#xD;
      preliminary anti-tumor activity, and pharmacodynamics (PD) of FT-7051 in men with metastatic&#xD;
      castration-resistant prostate cancer who have progressed despite prior therapy and had been&#xD;
      treated with at least one potent anti-androgen therapy.&#xD;
&#xD;
      The starting dose, 25 mg once daily (QD), of FT-7051 administered discontinuously (21 days&#xD;
      on/7 days off) in 28-day cycles.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 30, 2020</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicities (DLTs)</measure>
    <time_frame>Within first 4 weeks of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious adverse events (SAEs) and clinically relevant adverse events (AEs)</measure>
    <time_frame>The treatment duration, predicted average 26 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinical laboratory abnormalities as assessed by CTCAE v5.0</measure>
    <time_frame>The treatment duration, predicted average 26 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prostate-specific antigen (PSA): Percent Change from Baseline</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate-specific antigen (PSA): Maximum Decrease from Baseline</measure>
    <time_frame>The treatment duration, predicted average 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate-specific antigen (PSA): Time to Progression</measure>
    <time_frame>The treatment duration, predicted average 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to radiographic progression (rTTP)</measure>
    <time_frame>The treatment duration, predicted average 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate: radiographic response rate</measure>
    <time_frame>The treatment duration, predicted average 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response rate</measure>
    <time_frame>The treatment duration, predicted average 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>Blood samples for PK analysis collected at multiple visits during the first 90 days of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>Blood samples for PK analysis collected at multiple visits during the first 90 days of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of peak plasma concentration (Tmax)</measure>
    <time_frame>Blood samples for PK analysis collected at multiple visits during the first 90 days of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life (T 1/2)</measure>
    <time_frame>Blood samples for PK analysis collected at multiple visits during the first 90 days of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent plasma clearance (CL/F)</measure>
    <time_frame>Blood samples for PK analysis collected at multiple visits during the first 90 days of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution (Vd/F)</measure>
    <time_frame>Blood samples for PK analysis collected at multiple visits during the first 90 days of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Model-based estimate of change from baseline QT interval corrected using Fridericia's correction formula (QTcF) and 90% confidence interval at the estimated Cmax</measure>
    <time_frame>Electrocardiogram collected at multiple timepoints during the first 45 days of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Metastatic Castration-resistant Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Dose escalation study of FT-7051</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FT-7051</intervention_name>
    <description>Dose levels: Dose Level -1 through Dose Level 7, assigned per the protocol using a BOIN design. Additional dose levels may be explored as applicable.&#xD;
Capsules available in strengths of 10mg, 25mg, and 100 mg that are orally administered per the protocol frequency and dose level.</description>
    <arm_group_label>Dose escalation study of FT-7051</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Diagnosis of progressive metastatic castration-resistant prostate cancer (mCRPC)&#xD;
&#xD;
          -  Previously failed at least one potent anti-androgen therapy&#xD;
&#xD;
          -  Castrate levels of serum testosterone&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Adequate bone marrow function&#xD;
&#xD;
          -  Adequate kidney, heart and liver function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior solid organ transplant&#xD;
&#xD;
          -  Prior treatment with small molecules including chemotherapy, antibody, or other&#xD;
             experimental anticancer therapeutic within 4 weeks of first dose of study treatment&#xD;
&#xD;
          -  Prior radiation therapy within 4 weeks prior to initiation of study treatment&#xD;
             (including radiofrequency ablation)&#xD;
&#xD;
          -  Prior androgen antagonist therapy (enzalutamide, apalutamide, abiraterone acetate, or&#xD;
             darolutamide) within 2 weeks&#xD;
&#xD;
          -  Prior radium-223 therapy within 6 weeks&#xD;
&#xD;
          -  Symptomatic, untreated or actively progressing central nervous system (CNS) metastasis&#xD;
&#xD;
          -  Unstable or severe, uncontrolled medical condition (e.g., unstable cardiac function,&#xD;
             unstable pulmonary condition including pneumonitis and/or interstitial lung disease,&#xD;
             uncontrolled diabetes, active or uncontrolled infection requiring systemic therapy) or&#xD;
             any important medical illness or abnormal laboratory finding that would, in the&#xD;
             Investigator's judgement, increase the risk to the patient associated with&#xD;
             participation in the study&#xD;
&#xD;
          -  Concomitant medications that cause Torsades de Pointes that have not reached steady&#xD;
             state before first dose of the study drug&#xD;
&#xD;
          -  Concomitant medications that are strong inhibitors or inducers of CYP3A4 or an&#xD;
             inhibitor of P-gp&#xD;
&#xD;
          -  History of infection with human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Active infection with hepatitis B, or hepatitis C virus&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Von Potter, MD</last_name>
    <role>Study Director</role>
    <affiliation>Forma Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Forma Therapeutics</last_name>
    <phone>617-679-1970</phone>
    <email>medicalinformation@formatherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>HonorHealth</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joyce Schaffer, RN</last_name>
      <phone>480-323-1791</phone>
      <email>clinicaltrials@honorhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado Health</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jake Baldasare</last_name>
      <phone>720-848-9383</phone>
      <email>jake.baldasare@cuanschutz.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center of Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morgan Whipkey</last_name>
      <phone>312-695-1301</phone>
      <email>RHLCCCEPTInquiries@northwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland, Greenebaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Besche, BSN</last_name>
      <phone>410-328-8610</phone>
      <email>mbesche@umm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Atkocius</last_name>
      <phone>314-747-1343</phone>
      <email>a.atkocius@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mt. Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vibhaiv Patel</last_name>
      <phone>212-636-3856</phone>
      <email>vaibhav.patel@mountsinai.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University Health System</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Hurrelbrink, RN</last_name>
      <phone>919-681-7460</phone>
      <email>julia.hurrelbrink@duke.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carolina Urologic Research Center</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Floyd</last_name>
      <phone>843-449-1010</phone>
      <email>rfloyd@curcmb.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 24, 2020</study_first_submitted>
  <study_first_submitted_qc>October 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic Castration-resistant Prostate Cancer</keyword>
  <keyword>Prostate cancer</keyword>
  <keyword>Urogenital disease</keyword>
  <keyword>Prostatic disease</keyword>
  <keyword>Hormone antagonists</keyword>
  <keyword>Hormones, hormone substitutes</keyword>
  <keyword>FT-7051</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

